Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN L MCCUNE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1043215452
CMS profile
137445
Location
MARIETTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$111,917.66

120 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN L MCCUNE

NPI 1043215452 · CMS profile ID 137445

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MARIETTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043215452?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN L MCCUNE, NPI 1043215452, CMS profile ID 137445. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043215452?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). STEVEN L MCCUNE, NPI 1043215452, CMS profile ID 137445. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043215452?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
STEVEN L MCCUNE, NPI 1043215452, CMS profile ID 137445, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1043215452?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

120 matching records · $111,917.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 120 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–120 of 120.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $1,400.0004/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519765 CMS
E.R. Squibb & Sons, L.L.C. $109.4404/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519763 CMS
E.R. Squibb & Sons, L.L.C. $359.4404/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519755 CMS
E.R. Squibb & Sons, L.L.C. $120.5404/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519769 CMS
Genentech USA, Inc. $550.0004/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950666555 CMS
E.R. Squibb & Sons, L.L.C. $269.1004/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519741 CMS
E.R. Squibb & Sons, L.L.C. $4,780.0004/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519743 CMS
E.R. Squibb & Sons, L.L.C. $3,665.0004/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519887 CMS
E.R. Squibb & Sons, L.L.C. $8.7504/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519733 CMS
E.R. Squibb & Sons, L.L.C. $129.1804/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519775 CMS
E.R. Squibb & Sons, L.L.C. $539.1704/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519865 CMS
E.R. Squibb & Sons, L.L.C. $122.9204/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519875 CMS
E.R. Squibb & Sons, L.L.C. $24.0004/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519877 CMS
E.R. Squibb & Sons, L.L.C. $1,400.0004/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519725 CMS
Merck Sharp & Dohme LLC $17.4703/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944141159 CMS
E.R. Squibb & Sons, L.L.C. $2,235.0003/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519713 CMS
E.R. Squibb & Sons, L.L.C. $1,400.0002/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519711 CMS
Amgen Inc. $21.6102/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939944889 CMS
Amgen Inc. $20.4702/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939944891 CMS
Celgene Corporation $23.4501/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519709 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,379.42 110
PY2020 $32,101.88 53
PY2021 $102,146.49 88
PY2022 $111,917.66 120
PY2023 $112,095.82 92
PY2024 $52,277.59 85
PY2025 $12,635.96 72

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $469.66 2
PY2025 Principal investigator $2,388,421.94 127
PY2024 Recipient $13,979.36 6
PY2024 Principal investigator $3,388,675.71 152
PY2023 Recipient $5,123.43 4
PY2023 Principal investigator $3,199,315.64 295
PY2022 Recipient $2,540.00 4
PY2022 Principal investigator $2,950,719.39 225
PY2021 Recipient $4,760.00 8
PY2021 Principal investigator $2,560,219.47 224
PY2020 Recipient $1,694.00 1
PY2020 Principal investigator $2,434,456.25 620
PY2019 Principal investigator $2,131,035.78 317

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

129 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 2 Merck Sharp & Dohme LLC $8,792.20 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic Alterations No dispute reported 06/30/2026 1232923262
Principal investigator 1 Merck Sharp & Dohme LLC $5,270.37 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers PC
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cisplatin as First-Line Therapy in Participants with Advanced and,or Unresectable Biliary Tract Carcinoma No dispute reported 06/30/2026 1232927457
Principal investigator 1 Merck Sharp & Dohme LLC $44,449.53 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than No dispute reported 06/30/2026 1232928694
Principal investigator 1 Merck Sharp & Dohme LLC $7,672.19 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase MK-3475A Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types MK-3475A-F11 No dispute reported 06/30/2026 1232928888
Principal investigator 1 Merck Sharp & Dohme LLC $5,622.54 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers PC
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232931486
Principal investigator 1 Merck Sharp & Dohme LLC $56,019.54 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232935159
Principal investigator 1 Merck Sharp & Dohme LLC $10,300.50 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232939897
Principal investigator 1 SEAGEN INC. $1,757.00 12/09/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228726500
Recipient Novartis Pharmaceuticals Corporation $332.54 12/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291276
Principal investigator 1 BeOne Medicines Ltd. $94,320.00 12/01/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330357
Principal investigator 1 SEAGEN INC. $4,582.00 11/21/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228726965
Principal investigator 1 Merck Sharp & Dohme LLC $28,715.00 11/05/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232935157
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 10/24/2025 Non-covered Recipient Entity
NW GEORGIA ONC Ctrs
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336785
Principal investigator 1 BeOne Medicines Ltd. $110,040.00 10/21/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330303
Principal investigator 1 SEAGEN INC. $1,500.00 10/07/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228723544
Principal investigator 1 SEAGEN INC. $4,700.00 10/07/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228726520
Principal investigator 1 Merck Sharp & Dohme LLC $121.59 08/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants with EGFR-mutated, Advanced Non-squamous Non-small Cell Lung Cancer NSCLC Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors No dispute reported 06/30/2026 1232922880
Principal investigator 1 Merck Sharp & Dohme LLC $99,630.72 08/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Randomized, Open label, Phase 3 Study of MK-2870 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer with PD-L1 TPS Greater Than or Equal To 50 No dispute reported 06/30/2026 1232923238
Principal investigator 1 Merck Sharp & Dohme LLC $33,210.24 08/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer No dispute reported 06/30/2026 1232924146
Principal investigator 1 Merck Sharp & Dohme LLC $162.12 08/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L Advanced,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinoma, Gastroesophageal Junction Adenoca No dispute reported 06/30/2026 1232924238
Principal investigator 1 Merck Sharp & Dohme LLC $70,974.08 08/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than No dispute reported 06/30/2026 1232928696
Principal investigator 1 Merck Sharp & Dohme LLC $81.06 08/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
A Phase 1,2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers No dispute reported 06/30/2026 1232933350
Principal investigator 1 Merck Sharp & Dohme LLC $132,615.60 08/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232935161
Principal investigator 1 Mirati Therapeutics, Inc. $8,001.00 08/20/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, PC
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530896
Principal investigator 1 BeOne Medicines Ltd. $15,720.00 08/05/2025 Non-covered Recipient Entity
NW GEORGIA ONC Ctrs
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336937
Recipient Novartis Pharmaceuticals Corporation $137.12 08/05/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190292819
Principal investigator 1 Genentech, Inc. $2,550.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1211631360
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192143313
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192143317
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192143326
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192143330
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192144926
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192144931
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192144940
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192144944
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 07/29/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192144948
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 07/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192143309
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 07/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192143322
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 07/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192144922
Principal investigator 1 GlaxoSmithKline, LLC. $1,550.00 07/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192144935
Principal investigator 1 BeOne Medicines Ltd. $78,600.00 07/07/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330317
Principal investigator 1 Genentech, Inc. $4,738.00 07/02/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211631403
Principal investigator 1 Merck Sharp & Dohme LLC $7,125.00 07/02/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than No dispute reported 06/30/2026 1232928656
Principal investigator 1 SEAGEN INC. $650.00 07/01/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228742601
Principal investigator 1 SEAGEN INC. $500.00 07/01/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228743577
Principal investigator 1 Exelixis Inc. $22,430.00 06/26/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382828
Principal investigator 1 Exelixis Inc. $878.00 06/26/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382832
Principal investigator 1 Genentech, Inc. $23,715.00 06/25/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
INAVO123 No dispute reported 06/30/2026 1211631396
Principal investigator 1 SEAGEN INC. $1,600.00 06/25/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA No dispute reported 06/30/2026 1228791911
Principal investigator 1 Genentech, Inc. $5,648.00 06/23/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211631368
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 06/23/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192134182
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/23/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192134189
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 06/23/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192143302
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 06/23/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192143305
Principal investigator 1 Exelixis Inc. $3,118.85 06/20/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382830
Principal investigator 1 BeOne Medicines USA, Inc. $5,671.00 06/17/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326090
Principal investigator 1 BeOne Medicines USA, Inc. $4,851.00 06/16/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190331467
Principal investigator 1 SEAGEN INC. $1,750.00 06/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA No dispute reported 06/30/2026 1228789913
Principal investigator 1 SEAGEN INC. $9,350.00 06/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA No dispute reported 06/30/2026 1228790431
Principal investigator 1 BeOne Medicines USA, Inc. $1,902.00 05/30/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326088
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 05/27/2025 Non-covered Recipient Entity
NW GEORGIA ONC Ctrs
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336774
Principal investigator 1 Genentech, Inc. $100.00 05/27/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211631481
Principal investigator 1 Genentech, Inc. $500.00 05/27/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211631487
Principal investigator 1 Genentech, Inc. $1,264.00 05/21/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211631364
Principal investigator 1 Exelixis Inc. $2,704.00 05/19/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382818
Principal investigator 1 Exelixis Inc. $18,290.00 05/19/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382822
Principal investigator 1 Exelixis Inc. $9,941.00 05/19/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382824
Principal investigator 1 Exelixis Inc. $676.00 05/19/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382826
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,408.08 05/14/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1185544159
Principal investigator 1 AstraZeneca UK Limited $41,494.00 05/14/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185544161
Principal investigator 1 BeiGene, Ltd. $78,600.00 05/08/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322116
Principal investigator 1 BeiGene, Ltd. $15,720.00 05/01/2025 Non-covered Recipient Entity
NW GEORGIA ONC Ctrs
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323574
Principal investigator 1 Genentech, Inc. $518.40 05/01/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211631491
Principal investigator 1 Genentech, Inc. $5,200.00 04/28/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
GDC 9545 vs single agent endocrine therapy of physician s choice in HR 2L 3L mBC No dispute reported 06/30/2026 1211631495
Principal investigator 1 Genentech, Inc. $4,550.00 04/28/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
GDC 9545 vs single agent endocrine therapy of physician s choice in HR 2L 3L mBC No dispute reported 06/30/2026 1211631498
Principal investigator 1 Genentech, Inc. $3,705.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211631433
Principal investigator 1 BeOne Medicines USA, Inc. $2,412.00 04/22/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326092
Principal investigator 1 Exelixis Inc. $4,647.40 04/21/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382820
Principal investigator 1 Genentech, Inc. $8,570.00 04/09/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211631375
Principal investigator 1 Genentech, Inc. $676.00 04/08/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211631430
Principal investigator 1 BeOne Medicines USA, Inc. $1,700.00 04/07/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190338520
Principal investigator 1 Genentech, Inc. $8,743.00 04/02/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211631372
Principal investigator 1 BeOne Medicines USA, Inc. $3,950.50 03/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190327213
Principal investigator 1 BeOne Medicines USA, Inc. $5,165.00 03/25/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326086
Principal investigator 1 BeOne Medicines USA, Inc. $4,057.00 03/24/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190338515
Principal investigator 1 Genentech, Inc. $348.00 03/24/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631443
Principal investigator 1 Genentech, Inc. $101.00 03/24/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631447
Principal investigator 1 Genentech, Inc. $203.00 03/24/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631452
Principal investigator 1 Genentech, Inc. $744.00 03/24/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631456
Principal investigator 1 Genentech, Inc. $500.00 03/24/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631460
Principal investigator 1 Merck Sharp & Dohme LLC $4,550.00 03/24/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase MK-3475A Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types MK-3475A-F11 No dispute reported 06/30/2026 1232928886
Principal investigator 1 Exelixis Inc. $2,530.80 03/21/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382810
Principal investigator 1 Merck Sharp & Dohme LLC $18,086.00 03/19/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934938
Principal investigator 1 Merck Sharp & Dohme LLC $4,500.00 03/17/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment No dispute reported 06/30/2026 1232937008
Principal investigator 1 Genentech, Inc. $8,386.90 03/14/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1211631356
Principal investigator 1 ABBVIE INC. $20,190.00 03/07/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202461953
Principal investigator 1 BeiGene USA, Inc. $1,869.00 03/03/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321536
Principal investigator 1 SEAGEN INC. $11,775.00 02/27/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228773068
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,600.00 02/26/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 No dispute reported 06/30/2026 1185544165
Principal investigator 1 Eli Lilly and Company $76.65 02/25/2025 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187872365
Principal investigator 1 BeiGene, Ltd. $31,440.00 02/24/2025 Non-covered Recipient Entity
NW GEORGIA ONC Ctrs
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325306
Principal investigator 1 Genentech, Inc. $1,191.00 02/20/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1211631400
Principal investigator 1 Exelixis Inc. $7,835.60 02/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382808
Principal investigator 1 Genentech, Inc. $4,550.00 02/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211631412
Principal investigator 1 BeiGene, Ltd. $15,720.00 02/05/2025 Non-covered Recipient Entity
NW GEORGIA ONC Ctrs
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323600
Principal investigator 1 Genentech, Inc. $1,040.00 02/05/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631465
Principal investigator 1 BeiGene, Ltd. $125,760.00 01/30/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322120
Principal investigator 1 Genentech, Inc. $2,746.00 01/28/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211631420
Principal investigator 1 BeiGene USA, Inc. $1,902.00 01/27/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers - Marietta
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325212
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $299.32 01/27/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, PC
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235995209
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,550.00 01/27/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Center, P.c.
A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therapies. No dispute reported 06/30/2026 1235995221
Principal investigator 1 Exelixis Inc. $6,105.65 01/24/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382816
Principal investigator 1 Genentech, Inc. $5,604.00 01/24/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211631407
Principal investigator 1 Mirati Therapeutics, Inc. $31,480.00 01/24/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, PC
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530892
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,200.00 01/22/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Center, P.c.
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers No dispute reported 06/30/2026 1235995219
Principal investigator 1 Genentech, Inc. $202.00 01/21/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631469
Principal investigator 1 Genentech, Inc. $1,525.00 01/21/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631474
Principal investigator 1 Genentech, Inc. $203.00 01/21/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631477
Principal investigator 1 Genentech, Inc. $3,702.60 01/17/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Atezolizumab Carboplatin Etoposide Tiragolumab or Placebo in 1L ES SCLC No dispute reported 06/30/2026 1211631425
Principal investigator 1 BeiGene, Ltd. $31,440.00 01/14/2025 Non-covered Recipient Entity
NW GEORGIA ONC Ctrs
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325328
Principal investigator 1 AstraZeneca UK Limited $16,628.65 01/13/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185544163
Principal investigator 1 Merck Sharp & Dohme LLC $500.00 01/13/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers PC
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232931484
Principal investigator 1 Exelixis Inc. $133.20 01/09/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382812
Principal investigator 1 Genentech, Inc. $1,076.00 01/08/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211631416
Principal investigator 1 Genentech, Inc. $4,200.00 01/08/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211631427
Principal investigator 1 Genentech, Inc. $9,162.00 01/07/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1211631352
Principal investigator 1 Exelixis Inc. $592.00 01/03/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382814
Principal investigator 1 BeiGene, Ltd. $15,120.00 01/02/2025 Non-covered Recipient Entity
NW GEORGIA ONC Ctrs
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323658
Principal investigator 1 Novartis Pharmaceuticals Corporation $711,103.06 01/01/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190305015